Peña-Gutiérrez Irene, Olalla-Sastre Beatriz, Río Paula, Rodríguez-Madoz Juan R
Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain; Instituto de Investigaciones Sanitarias, Fundación Jiménez Díaz, Madrid, Spain.
Division of Hematopoietic Innovative Therapies, Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain; Instituto de Investigaciones Sanitarias, Fundación Jiménez Díaz, Madrid, Spain.
Cytotherapy. 2025 Mar;27(3):279-286. doi: 10.1016/j.jcyt.2024.10.010. Epub 2024 Nov 19.
The gene editing field has advanced rapidly since the development of the clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 system because of its applicability in precisely modifying the genome. Among its multiple applications, the correction of genetic diseases has emerged as a potential curative treatment for many disorders that have eluded a cure to date. Despite its efficiency in achieving therapeutic levels of correction, the unexpected adverse effects of editing due to CRISPR/Cas9 nuclease activity are a major concern when translating these new strategies to the clinic. Multiple in silico tools and empirical methods have been developed to evaluate these off-target edits as well as other adverse alterations of the genome, including rearrangements, not only in ex vivo experiments but also in in vivo experiments. In this review, we summarize the available methods for the assessment of off-target effects of CRISPR/Cas9 systems, highlighting their advantages and limitations. Special attention will be paid to their application in pre-clinical studies and clinical trials, both in the manufacturing product and in the long-term follow-up of patients.
自从成簇规律间隔短回文重复序列(CRISPR)/Cas9系统开发以来,基因编辑领域发展迅速,因为它适用于精确修饰基因组。在其多种应用中,纠正遗传疾病已成为治疗许多迄今尚无治愈方法的疾病的一种潜在的根治性疗法。尽管CRISPR/Cas9系统在实现治疗水平的纠正方面效率很高,但在将这些新策略转化为临床应用时,由于CRISPR/Cas9核酸酶活性导致的意外不良编辑效应是一个主要问题。已经开发了多种计算机工具和经验方法来评估这些脱靶编辑以及基因组的其他不良改变,包括重排,不仅用于体外实验,也用于体内实验。在这篇综述中,我们总结了评估CRISPR/Cas9系统脱靶效应的现有方法,突出了它们的优点和局限性。将特别关注它们在临床前研究和临床试验中的应用,包括在产品制造以及患者的长期随访中。